An Overview of the C-MET Signaling Pathway

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2011 Dec 1

PMID 22128289

Citations 393

Authors

Shawna Leslie Organ

Ming-Sound Tsao

Affiliations

Soon will be listed here.

Abstract

c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in proliferation, motility, migration and invasion. Although c-MET is important in the control of tissue homeostasis under normal physiological conditions, it has also been found to be aberrantly activated in human cancers via mutation, amplification or protein overexpression. This paper provides an overview of the c-MET signaling pathway, including its role in the development of cancers, and provides a rationale for targeting the pathway as a possible treatment option.

Citing Articles

Network pharmacology and experimental analysis reveal Ethyl caffeate delays osimertinib resistance in lung cancer by suppression of MET.

Sang S, Han Y, Zhou H, Kang X, Gong Y Cancer Cell Int. 2025; 25(1):99.

PMID: 40089772 DOI: 10.1186/s12935-025-03690-5.

Spatial Transcriptomic Analysis of Surgical Resection Specimens of Primary Head and Neck Squamous Cell Carcinoma Treated with Afatinib in a Window-of-Opportunity Study (EORTC90111-24111).

Beyaert S, Loriot A, Machiels J, Schmitz S Int J Mol Sci. 2025; 26(5).

PMID: 40076457 PMC: 11898532. DOI: 10.3390/ijms26051830.

Proteomic characterization of MET-amplified esophageal adenocarcinomas reveals enrichment of alternative splicing- and androgen signaling-related proteins.

Grothey B, Lyu S, Quaas A, Simon A, Jung J, Schroder W Cell Mol Life Sci. 2025; 82(1):112.

PMID: 40074836 PMC: 11904063. DOI: 10.1007/s00018-025-05635-7.

Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Saito S, Yoshino H, Yokoyama S, Tominaga M, Li G, Arima J Int J Mol Sci. 2025; 26(4).

PMID: 40004241 PMC: 11855069. DOI: 10.3390/ijms26041776.

Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC).

Mina S, Shanshal M, Leventakos K, Parikh K Cancers (Basel). 2025; 17(3).

PMID: 39941723 PMC: 11816067. DOI: 10.3390/cancers17030353.

References

Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen D, Chaganti R . Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res. 1990; 50(19):6417-22. View

Bhowmick N, Neilson E, Moses H . Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432(7015):332-7. PMC: 3050735. DOI: 10.1038/nature03096. View

Hiscox S, Hallett M, Puntis M, Nakamura T, Jiang W . Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers. Cancer Invest. 1997; 15(6):513-21. DOI: 10.3109/07357909709047592. View

Miller C, Lin L, Casper A, Lim J, Thomas D, Orringer M . Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene. 2005; 25(3):409-18. DOI: 10.1038/sj.onc.1209057. View

Forbes S, Bhamra G, Bamford S, Dawson E, Kok C, Clements J . The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008; Chapter 10:Unit 10.11. PMC: 2705836. DOI: 10.1002/0471142905.hg1011s57. View

Trusolino L, Comoglio P . Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002; 2(4):289-300. DOI: 10.1038/nrc779. View

Conrotto P, Corso S, Gamberini S, Comoglio P, Giordano S . Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene. 2004; 23(30):5131-7. DOI: 10.1038/sj.onc.1207650. View

Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E . Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992; 189(1):227-32. DOI: 10.1016/0006-291x(92)91548-5. View

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

10.

Bachleitner-Hofmann T, Sun M, Chen C, Tang L, Song L, Zeng Z . HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 2008; 7(11):3499-508. DOI: 10.1158/1535-7163.MCT-08-0374. View

11.

Liu C, Park M, Tsao M . Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 1992; 7(1):181-5. View

12.

Corso S, Comoglio P, Giordano S . Cancer therapy: can the challenge be MET?. Trends Mol Med. 2005; 11(6):284-92. DOI: 10.1016/j.molmed.2005.04.005. View

13.

Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S . A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994; 77(2):261-71. DOI: 10.1016/0092-8674(94)90318-2. View

14.

Weidner K, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W . Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 1996; 384(6605):173-6. DOI: 10.1038/384173a0. View

15.

Lai A, Abella J, Park M . Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 2009; 19(10):542-51. DOI: 10.1016/j.tcb.2009.07.002. View

16.

Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I . Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest. 1998; 78(9):1143-53. View

17.

Rahimi N, Tremblay E, McAdam L, Park M, Schwall R, Elliott B . Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ. 1996; 7(2):263-70. View

18.

Lengyel E, Prechtel D, Resau J, Gauger K, Welk A, Lindemann K . C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2004; 113(4):678-82. DOI: 10.1002/ijc.20598. View

19.

Smolen G, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H . Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006; 103(7):2316-21. PMC: 1413705. DOI: 10.1073/pnas.0508776103. View

20.

Park M, Dean M, Cooper C, Schmidt M, OBrien S, Blair D . Mechanism of met oncogene activation. Cell. 1986; 45(6):895-904. DOI: 10.1016/0092-8674(86)90564-7. View